ELVN
Enliven Therapeutics, Inc.·Healthcare
41.41
2.633%(−1.12)
Close PriceLast Updated: — ET
52W L: $14.7952W H: $48.53
Enliven Therapeutics, Inc.·Healthcare
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m.
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients and longer treatment duration BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced additional, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an abstract accepted for an oral presentation at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden and virtually.
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduced her direct Common Stock holdings by 61.54%, from 65,000 to 25,000 shares, while indirect holdings remained at zero.
